Bladder cancer patients get dual attack: immunotherapy plus radiation
NCT ID NCT02560636
First seen Jan 09, 2026 · Last updated May 13, 2026 · Updated 15 times
Summary
This early-stage trial tests the safety of combining an immunotherapy drug (pembrolizumab) with radiation therapy for people with advanced bladder cancer. About 34 participants will receive the drug before and during radiation, and then continue it for up to a year or longer. The goal is to find the best dose and see if the combination helps control the cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INVASIVE BLADDER CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
NIHR Biomedical Research Centre at RM and ICR (https://www.cancerbrc.org/)
Sutton, SM2 5PT, United Kingdom
Conditions
Explore the condition pages connected to this study.